Pharmacoepidemiology of testosterone prescribing in Australia, 2010-2023
Authors' conclusion
Male testosterone use is again approaching pre-2015 peak levels in Australia, potentially due to evasion of PBS regulations. The marked increase in female prescriptions likely reflects a rapid expansion of testosterone use as masculinizing GAHT.
Study context
- Population
- All Pharmaceutical Benefits Scheme (PBS) testosterone prescriptions in Australia, 2010–2023, by patient age, gender (mostly sex recorded at birth), prescriber type and indication
- Outcome
- Testosterone prescribing trends
- Follow-up
- 2010–2023
Methodological details2010–2023
- 2010–2023
Main finding
As reported in the abstract
Male testosterone prescriptions rose to a peak in 2014, fell to a nadir in 2016
30%
Male prescriptions in 2023 vs 2014 peak
98%
Female testosterone prescriptions rise 2010 to 2023, mainly to individuals aged 18-29 years
80-fold
New female prescriptions as share of all testosterone initiations in 2023
30%
Observational data: associations, not effects.
Original publication
Pharmacoepidemiology of testosterone prescribing in Australia, 2010-2023. Eur J Endocrinol. Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →